Navigation Links
Topline Results from Phase 2 Clinical Trial of Oral NKTR-118 Presented at 20th American Academy of Pain Management Annual Clinical Meeting (AAPM) in Phoenix
Date:10/10/2009

eloping novel therapeutics based on its PEGylation and advanced polymer conjugation technology platforms. Nektar's technology and drug development expertise have enabled nine approved products in the U.S. or Europe for partners, which include leading biopharmaceutical companies, including UCB's Cimzia® for rheumatoid arthritis and Crohn's Disease, Roche's PEGASYS® for hepatitis C and Amgen's Neulasta® for neutropenia. Nektar has created a robust pipeline of potentially high-value therapeutics to address unmet medical needs by leveraging and expanding its technology platforms to improve and enable molecules. Nektar is currently conducting clinical and preclinical programs in oncology, pain and other therapeutic areas. NKTR-102, PEGylated irinotecan, is currently in Phase 2 clinical studies in ovarian, breast and colorectal cancer. NKTR-105, PEGylated docetaxel, is currently in a Phase 1 clinical study in patients with refractory solid tumors.

Nektar is headquartered in San Carlos, California, with additional R&D operations in Huntsville, Alabama and Hyderabad, India. Further information about the company and its drug development programs and capabilities may be found online at http://www.nektar.com.

This press release contains forward-looking statements that reflect the company's current views regarding the scientific and commercial potential of NKTR-118, the results of the Phase 2 study for that drug candidate and the potential of the company's product development pipeline and technology platform. These forward-looking statements involve risks and uncertainties, including but not limited to: (i) NKTR-118 is in mid-stage clinical development and the risk of failure remains high and failure can unexpectedly occur at any stage prior to regulatory approval due to efficacy, safety or other factors; (ii) the timing or success of the commencement or end of clinical trials and comme
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. Topline Findings from Comparative Analysis of INVEGA(TM) and Quetiapine in Schizophrenia to be Postered at the 20th Annual U.S. Psychiatric and Mental Health Congress
2. HerbalScience Releases Results of Pilot Clinical Study on Efficacy of Its Proprietary Elderberry Extract in Addressing Flu-Like Symptoms
3. ThromboGenics Announces Results From a Phase IIa Trial Evaluating Microplasmin for the Treatment of Diabetic Macular Edema (MIVI II DME)
4. Transdel Pharmaceuticals to Host Conference Call and Webcast on Tuesday, October 6, 2009 to Announce Top-Line Phase 3 Study Results for Lead Topical Pain Drug Ketotransdel(R)
5. Peregrine Pharmaceuticals Reports Positive Results From Phase II Bavituximab Lung Cancer Trial
6. Biotel Announces Fourth Quarter and Year End Results
7. Intarcia Therapeutics, Inc. Presents Positive Results of ITCA 650 Phase 1b Study in Type 2 Diabetes at the European Association for the Study of Diabetes Conference
8. BioMarin to Host Third Quarter 2009 Financial Results Conference Call and Webcast on Wednesday, October 28 at 5:00 p.m. ET
9. InteKrin Therapeutics Presents Positive INT131 Phase 2b Results at the 45th Annual European Association for the Study of Diabetes Meeting
10. Encouraging HIV/AIDS Vaccine Trial Results Support GeoVax Labs, Inc. Strategy
11. Sinobiopharma Reports Highlights From Audited Financial Results for the Fiscal Year Ended May 31, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2009)... Dec. 15 Epeius Biotechnologies Corporation, an ... medicine, gained international validation of the cutting-edge science ... when scientists around the world rediscovered the ... locus of cancer pathogenesis and disease progression, and ... scientists at the NIH National Cancer Institute investigating ...
(Date:12/15/2009)... three Department of Energy (DOE) bio-energy research centers, has ... valuable intellectual property. , ... ... Surety, LLC , the leading provider of ... Joint BioEnergy Institute (JBEI), one of three Department of ...
(Date:12/15/2009)... Dec. 15 Repligen Corporation (Nasdaq: ... received $731,000 in research funding to support the ... from the Muscular Dystrophy Association (MDA). This ... toxicology testing and GMP manufacture of a drug ... the MDA not only provides important funding for ...
(Date:12/15/2009)... /PRNewswire-Asia-FirstCall/ -- China Sky One,Medical, Inc. ("China Sky ... ), a,leading fully integrated pharmaceutical company developing and ... ("PRC"), today,announced that the Company has 30 medicines ... the National Basic Medical Insurance, Industrial Injury Insurance,and ... The 30 medicines treat a variety of ...
Breaking Biology Technology:Scientists Rediscover Gene Target for Cancer Therapy 2Scientists Rediscover Gene Target for Cancer Therapy 3Joint BioEnergy Institute Selects Surety's AbsoluteProof to Protect the Integrity and Legally Defend the Authenticity of its Scientific Intellectual Property 2Joint BioEnergy Institute Selects Surety's AbsoluteProof to Protect the Integrity and Legally Defend the Authenticity of its Scientific Intellectual Property 3Joint BioEnergy Institute Selects Surety's AbsoluteProof to Protect the Integrity and Legally Defend the Authenticity of its Scientific Intellectual Property 4Joint BioEnergy Institute Selects Surety's AbsoluteProof to Protect the Integrity and Legally Defend the Authenticity of its Scientific Intellectual Property 5Repligen Receives Second Research Grant from the Muscular Dystrophy Association to Support Friedreich's Ataxia Preclinical Development Program 2Repligen Receives Second Research Grant from the Muscular Dystrophy Association to Support Friedreich's Ataxia Preclinical Development Program 3China Sky Medical, Inc. Has 30 Medicines that will Be Included in China's National Insurance Directory 2China Sky Medical, Inc. Has 30 Medicines that will Be Included in China's National Insurance Directory 3
... Dmitriy Ovcharenko, Rich Jarvis, , ... , ... experimental tool for reducing the expression of specific , ... function analysis, target , validation, ...
... Trace amounts of ribonuclease (RNase) , ... ubiquitous in the laboratory environment--on your skin, in the , ... bare hands or on anything left , ... or eliminate RNase contamination. However, determining which , ...
... , ... Cenix Pre-designed siRNAs to Human, Mouse, and Rat , ... Silencer Validated siRNAs , ... Superior siRNA Design Combined with High , Quality Custom RNA ...
Other Biology Technology:Delivering siRNAs to Difficult Cell Types 2Delivering siRNAs to Difficult Cell Types 3Delivering siRNAs to Difficult Cell Types 4Delivering siRNAs to Difficult Cell Types 5Delivering siRNAs to Difficult Cell Types 6Delivering siRNAs to Difficult Cell Types 7Combat RNase Contamination in the Lab 2Combat RNase Contamination in the Lab 3Combat RNase Contamination in the Lab 4Combat RNase Contamination in the Lab 5IMPROVE SILENCING SUCCESS: siRNAs THAT WORK BETTER! 2IMPROVE SILENCING SUCCESS: siRNAs THAT WORK BETTER! 3IMPROVE SILENCING SUCCESS: siRNAs THAT WORK BETTER! 4IMPROVE SILENCING SUCCESS: siRNAs THAT WORK BETTER! 5IMPROVE SILENCING SUCCESS: siRNAs THAT WORK BETTER! 6IMPROVE SILENCING SUCCESS: siRNAs THAT WORK BETTER! 7IMPROVE SILENCING SUCCESS: siRNAs THAT WORK BETTER! 8IMPROVE SILENCING SUCCESS: siRNAs THAT WORK BETTER! 9IMPROVE SILENCING SUCCESS: siRNAs THAT WORK BETTER! 10
(Date:12/11/2009)... increases, growers are being challenged to bring consistently ... bottom line, orchard owners are experimenting with new ... labor costs. , Hand thinning, a common practice ... is among the most labor-intensive of orchard practices, ... and, ultimately, prices paid by consumers. A research ...
(Date:12/11/2009)... children understand that green plants photosynthesize, absorb carbon ... profound global-scale effects that photosynthesis has had on ... the origins and evolution of photosynthesis is Jeffrey ... of Life Sciences. , Oxygen, one of the ... and their descendants (including algae and higher plants), ...
(Date:12/11/2009)... and degrade the diverse types of defective proteins and ... Sabine C. Horn, Professor Thomas Sommer, Professor Udo Heinemann ... for Molecular Medicine (MDC) Berlin-Buch, Germany, have now found ... complex that plays a critical role in the quality ... identification and disposal of various defectively produced proteins. ( ...
Breaking Biology News(10 mins):Horizontal string trimmer reduces labor costs, increases peach size 2'Extreme' genes shed light on origins of photosynthesis 2'Extreme' genes shed light on origins of photosynthesis 3MDC researchers identify a scaffold regulating protein disposal 2New Poll Finds Most Americans Support Including Treatment for Drug and Alcohol Addiction in National Health Care Reform 3B All Demographics Report Per 49043 1New Poll Finds Most Americans Support Including Treatment for Drug and Alcohol Addiction in National Health Care Reform 3B All Demographics Report Per 49043 2New Poll Finds Most Americans Support Including Treatment for Drug and Alcohol Addiction in National Health Care Reform 3B All Demographics Report Per 49043 3New Poll Finds Most Americans Support Including Treatment for Drug and Alcohol Addiction in National Health Care Reform 3B All Demographics Report Per 49043 4A Growing Number of Brits Cross the Atlantic for Donor Egg IVF Treatment at Shady Grove Fertility Center 49039 1A Growing Number of Brits Cross the Atlantic for Donor Egg IVF Treatment at Shady Grove Fertility Center 49039 2A Growing Number of Brits Cross the Atlantic for Donor Egg IVF Treatment at Shady Grove Fertility Center 49039 3VIDEO 3A Perot Systems Launches Xcelys 28TM 29 for Revenue Cycle Management 49036 1VIDEO 3A Perot Systems Launches Xcelys 28TM 29 for Revenue Cycle Management 49036 2VIDEO 3A Perot Systems Launches Xcelys 28TM 29 for Revenue Cycle Management 49036 3
... by an international consortium of scientists, including a team ... (IMB), will transform our understanding of how our genome ... being. , The findings of the consortium 'FANTOM', ... and Genome Science Laboratory and RIKEN Wako Institute, will ...
... unfolds, scientists must explain the dimensions and mechanisms of ... human populations and their impacts on the world increase, ... Forests are being cleared, burned, logged, fragmented, and overhunted ... altered in insidious ways by global climatic and atmospheric ...
... the seas and the ocean floors is a mystery for ... - including a biologist from the University of the Basque ... an oceanographic campaign to study this biodiversity of the seas ... Bellingshausen Sea , The expedition, aboard the oceanographic vessel, ...
Other Biology News:New insights into the software of life 2Scientists must offer solutions for conserving tropical forests in a rapidly changing world 2The Antarctic Ocean floor 2
... up to 6 strain chambers with precise uniaxial ... design ensures that cells grow over long periods ... This unit allows you to control the frequency ... unique strain settings. The instrument fits in a ...
... The Guava PCA-96 systems provide automated, ... a tray of microcentrifuge tubes. This flexible ... ideal for screening in basic research, target ... Like it's smaller cousin, the Guava PCA-96 ...
... 250 g monoclonal antibody irreversibly crosslinked ... ~13 g of PDH complex from heart ... bovine heart mitochondria for control immunocapture. ,The ... isolation of PDH from small amounts of ...
... cells permits studies of protein-protein interactions, protein ... transcription factor-mediated gene regulation. The most rapid ... specific protein in a mammalian cell is ... cell. ProteoJuice Protein Transfection Reagent is an ...
Biology Products: